+44 20 8123 2220
info@marketpublishers.com

Congenital Hyperinsulinism - Pipeline Insight, 2021

https://marketpublishers.com/r/CE3072AB412CEN.html
Date: July 2021
Pages: 60
Price: US$ 1,500.00 (Single User License)
ID: CE3072AB412CEN

Abstracts

This report can be delivered to the clients within 24 hours

DelveInsight's, "Congenital Hyperinsulinism - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Congenital Hyperinsulinism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Congenital Hyperinsulinism Understanding

Congenital Hyperinsulinism: Overview

Congenital hyperinsulinism (CHI) is a heterogenous and complex disorder in which the unregulated insulin secretion from pancreatic beta-cells leads to hyperinsulinaemic hypoglycaemia. The severity of hypoglycaemia varies depending on the underlying molecular mechanism and genetic defects. The genetic and molecular causes of CHI include defects in pivotal pathways regulating the secretion of insulin from the beta-cell. The symptoms of CHI include irritability, sleepiness, lethargy, excessive hunger and rapid heart rate. The diagnosis of congenital hyperinsulinism is based on history, laboratory findings, and genetic testing. Prompt diagnosis and establishment of effective treatment are essential to avoid neurologic damage. Medical therapy and surgical intervention are the treatment for CHI.

+44 20 8123 2220
info@marketpublishers.com

'Congenital Hyperinsulinism - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Congenital Hyperinsulinism pipeline landscape is provided which includes the disease overview and Congenital Hyperinsulinism treatment guidelines. The assessment part of the report embraces, in depth Congenital Hyperinsulinism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Congenital Hyperinsulinism collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

> The companies and academics are working to assess challenges and seek opportunities that could influence Congenital Hyperinsulinism R&D. The therapies under development are focused on novel approaches to treat/improve Congenital Hyperinsulinism.

Congenital Hyperinsulinism Emerging Drugs Chapters

This segment of the Congenital Hyperinsulinism report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Congenital Hyperinsulinism Emerging Drugs

> Dasiglucagon: Zealand Pharma

Dasiglucagon is an analog of human glucagon that is stable in aqueous formulation. The drug is sold under the brand name Zegalogue for the treatment of hypoglycemia. In 2017, the US FDA and the European Commission both granted Orphan Drug designation to dasiglucagon for the treatment of CHI. The drug is in Phase III clinical studies for the treatment of CHI.

+44 20 8123 2220
info@marketpublishers.com

Further product details are provided in the report……..

Congenital Hyperinsulinism: Therapeutic Assessment

This segment of the report provides insights about the different Congenital Hyperinsulinism drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Congenital Hyperinsulinism

There are approx. 5+ key companies which are developing the therapies for Congenital Hyperinsulinism. The companies which have their Congenital Hyperinsulinism drug candidates in the most advanced stage, i.e. Phase III include, Zealand Pharma.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Congenital Hyperinsulinism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

+44 20 8123 2220
info@marketpublishers.com

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Congenital Hyperinsulinism: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Congenital Hyperinsulinism therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

+44 20 8123 2220
info@marketpublishers.com

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Congenital Hyperinsulinism drugs.

Congenital Hyperinsulinism Report Insights

- Congenital Hyperinsulinism Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs

Congenital Hyperinsulinism Report Assessment

- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Congenital Hyperinsulinism drugs?
- How many Congenital Hyperinsulinism drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Congenital Hyperinsulinism?

+44 20 8123 2220
info@marketpublishers.com

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Congenital Hyperinsulinism therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Congenital Hyperinsulinism and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Zealand Pharma

Eiger BioPharmaceuticals

Crinetics Pharmaceuticals

AmideBio

Hanmi Pharmaceutical Company Limited

Key Products

Dasiglucagon

Avexitide

CRN-04777

AB-G023

HM15136

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Congenital Hyperinsulinism - Pipeline Insight, 2021
Product link: https://marketpublishers.com/r/CE3072AB412CEN.html
Price: US$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/CE3072AB412CEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970